JP2018501215A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501215A5
JP2018501215A5 JP2017529357A JP2017529357A JP2018501215A5 JP 2018501215 A5 JP2018501215 A5 JP 2018501215A5 JP 2017529357 A JP2017529357 A JP 2017529357A JP 2017529357 A JP2017529357 A JP 2017529357A JP 2018501215 A5 JP2018501215 A5 JP 2018501215A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
salt according
salt
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017529357A
Other languages
English (en)
Japanese (ja)
Other versions
JP6550132B2 (ja
JP2018501215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/058965 external-priority patent/WO2016087975A1/en
Publication of JP2018501215A publication Critical patent/JP2018501215A/ja
Publication of JP2018501215A5 publication Critical patent/JP2018501215A5/ja
Application granted granted Critical
Publication of JP6550132B2 publication Critical patent/JP6550132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017529357A 2014-12-03 2015-11-19 Cd38阻害剤及び治療の方法 Active JP6550132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
US62/086,844 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (3)

Publication Number Publication Date
JP2018501215A JP2018501215A (ja) 2018-01-18
JP2018501215A5 true JP2018501215A5 (enExample) 2018-11-01
JP6550132B2 JP6550132B2 (ja) 2019-07-24

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529357A Active JP6550132B2 (ja) 2014-12-03 2015-11-19 Cd38阻害剤及び治療の方法

Country Status (11)

Country Link
US (1) US9840496B2 (enExample)
EP (1) EP3227275B1 (enExample)
JP (1) JP6550132B2 (enExample)
KR (1) KR20170090478A (enExample)
CN (1) CN107428733A (enExample)
AU (1) AU2015356721B2 (enExample)
BR (1) BR112017011642A2 (enExample)
CA (1) CA2969178A1 (enExample)
ES (1) ES2717260T3 (enExample)
RU (1) RU2017121002A (enExample)
WO (1) WO2016087975A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3544612A4 (en) * 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
US11535621B2 (en) * 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
WO2021087087A1 (en) 2019-10-30 2021-05-06 Mitobridge Inc. N-cyclohexyl-5-(thiazol-5-yl)-1h-indole-7-carboxamide derivatives and related compounds as cd38 inhibitors for increasing nad+ and for the treatment of e.g. muscular disorders
AR121759A1 (es) * 2020-04-07 2022-07-06 Mitobridge Inc Inhibidores de cd38
CN116710090A (zh) * 2020-10-09 2023-09-05 Napa医疗有限公司 Cd38的杂芳基酰胺抑制剂
TW202241418A (zh) 2021-01-29 2022-11-01 美商律幫治療股份有限公司 作為cd38之抑制劑的喹啉及氮雜喹啉
KR20240001709A (ko) * 2021-04-30 2024-01-03 난징 이뮤노파지 바이오테크 코., 엘티디. 화합물 및 cd38 억제제로서의 용도
CA3225785A1 (en) * 2021-07-12 2023-01-19 Cytokinetics, Inc. Cd38 modulators and methods of use thereof
WO2024254396A1 (en) * 2023-06-07 2024-12-12 Flagship Pioneering Innovations, Vi, Llc Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026090190A1 (en) * 2024-10-22 2026-04-30 Aeovian Pharmaceuticals, Inc. Cd38 modulators and uses thereof
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433840C (en) * 2001-01-04 2010-05-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
WO2010025235A1 (en) * 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors

Similar Documents

Publication Publication Date Title
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2017514910A5 (enExample)
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
JP2013032389A5 (enExample)
JP2015537020A5 (enExample)
MX373436B (es) Compuesto peptidico.
JP2016505637A5 (enExample)
RU2017121002A (ru) Ингибиторы CD38 и способы лечения
EP3954679A3 (en) Amide compounds for the treatment of hiv infections
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
JP2016528301A5 (enExample)
JP2017501237A5 (enExample)
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
JP2018521020A5 (enExample)
JP2017537066A5 (enExample)
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
JP2016518437A5 (enExample)
MX2015001571A (es) Compuestos de anillo en puente como inhibidores del virus de la hepatitis c (hcv) y sus aplicaciones farmaceuticas.
JP2015516427A5 (enExample)
JP2015536325A5 (enExample)
RU2018113718A (ru) Новые соединения
EP4599830A3 (en) Isoxazoline compounds for use in treating demodicosis
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
JP2016529315A5 (enExample)
JP2015521195A5 (enExample)